MedTrace Logo

Buprenorphine vs Buprenorphine/Naloxone on the Effects of Maternal Symptomatology

NCT03740243 · Status: WITHDRAWN · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2020-03-24

No results posted yet for this study

Summary

This study will assesses the efficacy of buprenorphine/naloxone vs buprenorphine on maternal withdrawal symptoms and drug cravings.

This is a randomized controlled trial to a cohort of pregnant women seeking medication-assisted treatment for opioid use disorders. Half of participants will receive buprenorphine, while the other half of participants receive a combination of buprenorphine/naloxone

Conditions

  • Opioid-use Disorder

Interventions

DRUG

Buprenorphine/naloxone

Buprenorphine/naloxone tablet or film

DRUG

Buprenorphine

Buprenorphine tablet

Sponsors & Collaborators

Principal Investigators

  • David J Garry, DO · Stony Brook University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-11-30
Primary Completion
2020-03-22
Completion
2020-03-22
FDA Drug
Yes

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03740243 on ClinicalTrials.gov